Acetylcholinesterase Inhibitors and Sleep Architecture in Patients with Alzheimer’s Disease


Background and objective

Studies suggest that some acetylcholinesterase inhibitors (AChEIs) increase rapid eye movement (REM) sleep and nightmares in patients with Alzheimer’s disease (AD) but few have studied their effect on other sleep parameters. The objective of this study was to examine differences in sleep architecture in AD patients taking different AChEIs.


76 participants (51 men, 25 women) [mean age = 78.2 years; SD = 7.7] with mild to moderate AD underwent medication history screening as well as polysomnography to determine the percentage of each sleep stage. Participants were divided into groups based on AChEI used: donepezil (n = 41), galantamine (n = 15), rivastigmine (n = 8) or no AChEI (n = 12). General univariate linear model analyses were performed.


AChEI therapy had a significant effect on the percentage of stage 1 (p = 0.01) and stage 2 (p = 0.03) sleep. Patients in the donepezil group had a significantly lower percentage of stage 1 sleep than patients in the galantamine group (mean = 17.3%, SD = 11.7 vs 29.2%, SD = 15.0, respectively; p = 0.01), but there was no significant difference between the donepezil group and the rivastigmine (mean = 25.0%, SD = 12.3) or no AChEI groups (mean = 27.6%, SD = 17.7) in this respect. No significant differences in percentage of stage 1 between other groups were seen. Patients in the donepezil group also had a significantly higher percentage of stage 2 sleep than patients in the no AChEI group (mean = 63.6%, SD = 14.4 vs 51.4%, SD = 16.9, respectively; p = 0.04), but there was no significant difference between the donepezil group and either the galantamine group (mean = 56.5%, SD = 8.7) or the rivastigmine group (mean = 59.9%, SD = 8.4). There were no significant differences between groups in terms of percentage REM sleep or other sleep parameters.


Subgroups of AD patients (classified according to AChEI treatment) in this study differed with respect to the amount of stage 1 and stage 2 sleep experienced, with the donepezil-treated group having the lowest percentage of stage 1 sleep and the highest percentage of stage 2 sleep. There was no significant difference in the amount of REM sleep between the groups. Our data suggest that sleep architecture may be affected by the use of donepezil in patients with AD. Although not elicited in this study because of the small sample size, there may be a class effect of AChEIs on sleep architecture. Double-blind, placebo-controlled studies are needed to better understand causality and the effect of each AChEI on sleep architecture in patients with AD.

This is a preview of subscription content, access via your institution.

Table I
Table II
Table III
Table IV
Table V


  1. 1.

    A ‘first-night effect’ refers to the disrupted or abnormal sleep architecture (manifested as an increased percentage of stage 1 sleep with resultant decreases in the other sleep stages) commonly seen on the first night of in-laboratory sleep recordings. Typically, the patient adapts to the laboratory setting on the second night of recordings.


  1. 1.

    Mayeux R, Sano M. Treatment of Alzheimer’s disease. N Eng J Med 1999; 341(22): 1670–9

    Article  CAS  Google Scholar 

  2. 2.

    Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56(9): 1154–66

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Small G, Rabins P, Barry P, et al. Diagnosis and treatment of Alzheimer’s disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. JAMA 1997; 278(16): 1363–71

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Nordberg A, Svensson A-L. Cholinesterase inhibitors in the treatment of Alzheimer’s disease. Drug Saf 1998; 19(6): 465–80

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    Hobson JA. A new model of brain-mind state: activation level, input source, and mode of processing (AIM). In: Antrobus JS, Bertini M, editors. The neuropsychology of sleep and dreaming. Mahwah (NJ): Lawrence Erlbaum Assoc., 1992: 227–47

    Google Scholar 

  6. 6.

    Mizuno S, Kameda A, Inagaki T, et al. Effects of donepezil on Alzheimer’s disease: the relationship between cognitive function and rapid eye movement sleep. Psychiatry Clin Neurosci 2004; 58: 660–5

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Stahl SM, Markowitz JS, Papadopoulos G, et al. Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer’s disease. Curr Med Res Opin 2004; 20(4): 517–24

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Schredl M, Weber B, Leins M-L, et al. Donepezil-induced REM sleep augmentation enhances memory performance in elderly, healthy persons. Exp Gerontol 2001; 36: 353–61

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer’s disease: results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10(3): 237–44

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Ross JS, Shua-Haim JR. Aricept-induced nightmares in Alzheimer’s disease: 2 case reports. J Am Geriatr Soc 1998; 46(1): 119–20

    PubMed  CAS  Google Scholar 

  11. 11.

    Schredl M, Weber B, Braus D, et al. The effect of rivastigmine on sleep in elderly healthy subjects. Exp Gerontol 2000; 35: 243–9

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Holsboer-Trachsler E, Hatzinger M, Stohler R, et al. Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man. Neuropsychopharmacology 1993; 8(1): 87–92

    PubMed  CAS  Google Scholar 

  13. 13.

    McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984; 34: 939–44

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Rechtschaffen A, Kales A, editors. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Los Angeles (CA): Brain Information Service, Brain Research Institute, UCLA, 1973

    Google Scholar 

  16. 16.

    Bonnet M, Carley D, Carskadon MA, et al. EEG arousals: scoring rules and examples. Sleep 1992; 15: 171–84

    Google Scholar 

  17. 17.

    Loredo JS, Ancoli-Israel S, Dimsdale JE. Effect of continuous positive airway pressure vs placebo continuous positive airway pressure on sleep quality in obstructive sleep apnea. Chest 1999; 116(6): 1545–9

    PubMed  Article  CAS  Google Scholar 

  18. 18.

    SPSS for Windows, Version 12.0.0. Chicago (IL): SPSS Inc., 2005

  19. 19.

    Broughton R, Fleming J, Fleetham J. Home assessment of sleep disorders by portable monitoring. J Clin Neurophysiol 1996; 13(4): 272–84

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Sharpley AL, Solomon RA, Cowen PJ. Evaluation of first night effect using ambulatory monitoring and automatic sleep stage analysis. Sleep 1988; 11(3): 273–6

    PubMed  CAS  Google Scholar 

  21. 21.

    McCall WV, Erwin CW, Edinger JD, et al. Ambulatory polysomnography: technical aspects and normative values. J Clin Neurophysiol 1992; 9(1): 68–77

    PubMed  Article  CAS  Google Scholar 

  22. 22.

    Markowitz JS, Gutterman EM, Lilienfeld S, et al. Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine. Sleep 2003; 26(5): 602–6

    PubMed  Google Scholar 

  23. 23.

    Ancoli-Israel S, Amatniek J, Ascher S, et al. Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer’s disease and their caregivers: a double-blind, head-to-head, randomized pilot study. Alzheimer Dis Assoc Disord 2005; 19(4): 240–5

    PubMed  Article  CAS  Google Scholar 

  24. 24.

    Nochi S, Asakawa N, Sato T. Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020). Biol Pharm Bull 1995; 18(8): 1145–7

    PubMed  Article  CAS  Google Scholar 

Download references


The authors would like to thank Deborah Greenfield for participant recruitment and data collection. This study was supported by grants from the National Institute of Aging (NIA AG08415, NIA P50 AG05131) and the National Institutes of Health (NIH M01 RR008270) and by the Research Service of the Veterans Affairs San Diego Healthcare System. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information



Corresponding author

Correspondence to Dr Sonia Ancoli-Israel.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cooke, J.R., Loredo, J.S., Liu, L. et al. Acetylcholinesterase Inhibitors and Sleep Architecture in Patients with Alzheimer’s Disease. Drugs Aging 23, 503–511 (2006).

Download citation


  • Rivastigmine
  • Galantamine
  • Sleep Architecture
  • Percentage Stage
  • Periodic Limb Movement Index